PD-1 抗体与 EZH2 抑制剂联合治疗前列腺癌：从机制解析到临床转化

阔 张(承德医学院附属医院，中国)
辉 徐(承德医学院附属医院，中国)

摘要

前列腺癌是全球男性最常见的恶性肿瘤之一，其治疗在晚期阶段面临巨大挑战，尤其是转移性去势抵抗性前列腺。尽管近年来靶向治疗和新型内分泌治疗取得了进展，但免疫治疗在前列腺癌领域的应用却步履维艰。前列腺癌通常被认为是免疫学上的“冷肿瘤”，其特征包括低肿瘤突变负荷、免疫排斥表型以及肿瘤微环境中T细胞浸润不足。在这一背景下，本文旨在系统综述PD-1抗体与EZH2抑制剂联合治疗前列腺癌的转化医学前景。通过整合机制解析与临床转化视角，本综述期望为开发更有效的前列腺癌免疫联合疗法提供理论依据和策略参考。

关键词

前列腺癌；PD-1抗体；EZH2抑制剂；免疫治疗

参考

MOREL KL, SHEAHAN AV, BURKHART DL, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer[J].Nature Cancer,2021,2(4):444-456.

CIMADAMORE A, BOIXAREU C, SHARP A, et al. Novel Therapeutic Strategies for Metastatic ProstateCancerCare[J].European Urology,2025,88(5):437-448.

RUNCIE KD, DALLOS MC. Prostate Cancer Immunotherapy-Finally in From the Cold?[J]. Current Oncology Reports, 2021, 23(8): 88.

TANG M, GONG M, LIU X, et al. Recent update on the development of EZH2 inhibitors and degraders for cancer therapy[J]. European Journal of Medicinal Chemistry, 2025, 299: 118106.

JAMES JL, TAYLOR BC, AXELROD ML, et al. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance[J]. Journal for ImmunoTherapy of Cancer, 2023, 11(11).

LIAO Y, CHEN CH, XIAO T, et al. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress[J]. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(3).

MORTEZAE K. EZH2 regulatory roles in cancer immunity and immunotherapy[J]. Pathology Research and Practice, 2025, 270: 155992.

HUANG R, WU Y, ZOU Z. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects[J]. Epigenomics, 2022, 14(22): 1449-1464.

GODFREY J, LIU H, YU J, et al. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation[J]. Blood Advances, 2023, 7(6): 963-970.

WANG X, HE J, DING G, et al. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies[J]. Frontiers in Immunology, 2025, 16: 1688699.

LABRIOLA MK, ATIQ S, HIRSHMAN N, et al. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies[J]. Prostate Cancer and Prostatic Diseases, 2021, 24(2): 301-309.

PATEL D, MCKAY R, PARSONS JK. Immunotherapy for Localized Prostate Cancer: The Next Frontier?[J]. The Urologic Clinics of North America, 2020, 47(4): 443-456.

FAY EK, GRAFF JN. Immunotherapy in Prostate Cancer[J]. Cancers, 2020, 12(7).

WAN G, LI S, TANG Q, et al. An updated patent review of EZH2 inhibitors (2024-present)[J]. Expert Opinion on Therapeutic Patents, 2025, 35(6): 597-610.

BOLDRINI L, FAVIANA P, GALLI L, et al. Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database[J]. Genes, 2021, 12(9).

BERNAL A, BECHLER AJ, MOHAN K, et al. The Current Therapeutic Landscape for Metastatic Prostate Cancer[J]. Pharmaceuticals, 2024, 17(3).

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v9i3.37291